Inga Nehlmeier

Inga Nehlmeier

Auto-generated profile, based on publicly available information

Inga Nehlmeier

Infection Biology Unit, German Primate Center – Leibniz Institute for Primate Research, Göttingen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
KMKristin Metzdorf
Kristin Metzdorf
HJHenning Jacobsen
Henning Jacobsen
MGMarina C. Greweling-Pils
Marina C. Greweling-Pils
MHMarkus Hoffmann
Markus Hoffmann
TLTatjana Lüddecke
Tatjana Lüddecke
LCLuka Cicin-Sain
Luka Cicin-Sain
The COVID-19 pandemic remains a global health threat and novel antiviral strategies are urgently needed. SARS-CoV-2 employs the cellular serine protease TMPRSS2 for entry into lung cells, and TMPRSS2 inhibitors are being developed for COVID-19 therapy. However, the SARS-CoV-2 Omicron variant, which currently dominates the pandemic, prefers the endo/lysosomal cysteine protease cathepsin L over TMPRSS2 for cell entry, raising doubts as to whether TMPRSS2 inhibitors would be suitable for the treatment of patients infected with the Omicron variant. Nevertheless, the contribution of TMPRSS2 to the spread of SARS-CoV-2 in the infected host is largely unclear. In this study, we show that the loss of TMPRSS2 strongly reduced the replication of the Beta variant in the nose, trachea and lung of C57BL/6 mice, and protected the animals from weight loss and disease. The infection of mice with the Omicron variant did not cause disease, as expected, but again, TMPRSS2 was essential for efficient viral spread in the upper and lower respiratory tract. These results identify the key role of TMPRSS2 in SARS-CoV-2 Beta and Omicron infection, and highlight TMPRSS2 as an attractive target for antiviral intervention.

28 September 2021 in Cell Reports
Verified
Journal Article
Open access
PAPrerna Arora
Prerna Arora
ASAnzhalika Sidarovich
Anzhalika Sidarovich
NKNadine Krüger
Nadine Krüger
AKAmy Kempf
Amy Kempf
INInga Nehlmeier
Inga Nehlmeier
MHMarkus Hoffmann
Markus Hoffmann
The Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), B.1.617.2, emerged in India and has spread to over 80 countries. B.1.617.2 replaced B.1.1.7 as the dominant virus in the United Kingdom, resulting in a steep increase in new infections, and a similar development is expected for other countries. Effective countermeasures require information on susceptibility of B.1.617.2 to control by antibodies elicited by vaccines and used for coronavirus disease 2019 (COVID-19) therapy. We show, using pseudotyping, that B.1.617.2 evades control by antibodies induced upon infection and BNT162b2 vaccination, although to a lesser extent as compared to B.1.351. We find that B.1.617.2 is resistant against bamlanivimab, a monoclonal antibody with emergency use authorization for COVID-19 therapy. Finally, we show increased Calu-3 lung cell entry and enhanced cell-to-cell fusion of B.1.617.2, which may contribute to augmented transmissibility and pathogenicity of this variant. These results identify B.1.617.2 as an immune evasion variant with increased capacity to enter and fuse lung cells.

3 March 2023 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
MHMarkus Hoffmann
Markus Hoffmann
PAPrerna Arora
Prerna Arora
INInga Nehlmeier
Inga Nehlmeier
AKAmy Kempf
Amy Kempf
ACAnne Cossmann
Anne Cossmann
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann
Since late 2022, the share of infections caused by the SARS-CoV-2 lineage XBB.1.5 has gradually increased in the United States, resulting in XBB.1.5 becoming the dominating SARS-CoV-2 lineage in the United States and a similar trend is likely to soon take place also in European countries. However, information on the virological properties of XBB.1.5 is scarce. Here, we conducted an initial virological assessment of the SARS-CoV-2 XBB.1.5 lineage. The SARS-CoV-2 XBB lineage possesses an extraordinarily high capacity for antibody evasion due to its unique set of S protein mutations [1-4]. However, this trait may have come at the cost of a moderately reduced host cell entry efficiency as suggested by recent in vitro data [1, 5], which may explain why infections caused by XBB sublineages only accounted for a small proportion of total SARS-CoV-2 infections in several countries (except India) so far (Fig. 1a). Recently, this trend has changed for the United States, where the share of infections caused by SARS-CoV-2 sublineage XBB.1.5 has gradually increased since late 2022, and XBB.1.5 now represents the dominating SARS-CoV-2 lineage (Fig. 1a). Moreover, although being presently detected at low frequencies only, a similar increase in the share of XBB.1.5-related infections is also observed for European countries (Fig. 1a). The XBB.1.5 S protein differs by only one mutation (S486P) from the S protein of the parental XBB.1 lineage, and this mutation is located in the receptor-binding domain (RBD) (Fig. 1b). Thus, it may affect transmissibility by modulating cell entry efficiency, and may alter sensitivity to antibody-mediated neutralization. Here, we performed an assessment on the host cell entry efficiency of the SARS-CoV-2 XBB.1.5 lineage and its sensitivity to antibody-mediated neutralization, using S protein-bearing pseudovirus particles (pp), which are a suitable model system for the analysis of SARS-CoV-2 host cell entry and its neutralization [6]. Particles pseudotyped with the S protein of the ancestral B.1 lineage (B.1 pp) or Omicron sublineages BA.4/BA.5 (identical on amino acid level, BA.4-5 pp), BQ.1.1 (BQ.1.1 pp), or XBB.1 (XBB.1 pp) were used for comparison. First, we compared cell line tropism and host cell entry efficiency of the different pseudoviruses. As expected, BA.4-5 pp displayed augmented cell entry efficiency compared to B.1 pp for most cell lines tested with the exception

13 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHMarkus Hoffmann
Markus Hoffmann
LWLok-Yin Roy Wong
Lok-Yin Roy Wong
PAPrerna Arora
Prerna Arora
LZLu Zhang
Lu Zhang
CRCheila Rocha
Cheila Rocha
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann
The SARS-CoV-2 Omicron subvariants BA.1 and BA.2 exhibit reduced lung cell infection relative to previously circulating SARS-CoV-2 variants, which may account for their reduced pathogenicity. However, it is unclear whether lung cell infection by BA.5, which displaced these variants, remains attenuated. Here, we show that the spike (S) protein of BA.5 exhibits increased cleavage at the S1/S2 site and drives cell-cell fusion and lung cell entry with higher efficiency than its counterparts from BA.1 and BA.2. Increased lung cell entry depends on mutation H69Δ/V70Δ and is associated with efficient replication of BA.5 in cultured lung cells. Further, BA.5 replicates in the lungs of female Balb/c mice and the nasal cavity of female ferrets with much higher efficiency than BA.1. These results suggest that BA.5 has acquired the ability to efficiently infect lung cells, a prerequisite for causing severe disease, suggesting that evolution of Omicron subvariants can result in partial loss of attenuation.

25 October 2021 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
PAPrerna Arora
Prerna Arora
CRCheila Rocha
Cheila Rocha
AKAmy Kempf
Amy Kempf
INInga Nehlmeier
Inga Nehlmeier
LGLuise Graichen
Luise Graichen
MHMarkus Hoffmann
Markus Hoffmann

8 May 2023 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
INInga Nehlmeier
Inga Nehlmeier
AKAmy Kempf
Amy Kempf
PAPrerna Arora
Prerna Arora
ACAnne Cossmann
Anne Cossmann
AJAlexandra Jablonka
Alexandra Jablonka
MHMarkus Hoffmann
Markus Hoffmann
Despite previous circulation of the highly transmissible and antibody evasive BA.2.75, BQ.1, XBB.1 and XBB.1.5 lineages, the share of infections caused by the SARS-CoV-2 lineage XBB.1.16 has gradually increased in India in early 2023, resulting in XBB.1.16 being the dominating SARS-CoV-2 lineage in India today. Since a similar trend may also take place in other countries and information on the biological properties of the XBB.1.16 lineage is scarce, we conducted a rapid assessment of the SARS-CoV-2 XBB.1.16 lineage with respect to its ability to enter cells and evade neutralisation by antibodies. The newly emerged SARS-CoV-2 XBB.1.16 lineage (also dubbed as Arcturus), which harbours a unique combination of spike (S) protein mutations (Fig. 1a), was first described in India in January 2023 and rapidly became the dominating lineage (https://covspectrum.org/ [1]) (Fig. 1b). Here we performed a rapid assessment of the SARS-CoV-2 XBB.1.16 lineage regarding its ability to enter cells and evade neutralisation by antibodies using S proteincarrying pseudovirus particles (pp), which constitute a suitable model to study host cell entry of SARS-CoV-2 and its neutralisation [2]. For comparison, particles bearing the S protein of the ancestral B.1 lineage (B.1 pp) or S proteins of Omicron sublineages BA.5 (BA.5 pp), CH.1.1 (CH.1.1 pp), XBB.1 (XBB.1 pp), or XBB.1.5 (XBB.1.5 pp) were used. In line with expectations, BA.5 pp entered Vero (African green monkey, kidney), 293 T (human, kidney) and Huh-7 (human, liver) cells with higher efficiency compared to B.1 pp (1.6-3.9x higher, respectively), while entry into Caco-2 (human, colon) and Calu-3 (human, lung) cells was less efficient (1.6-1.9x reduced, compared to B.1 pp) [3] (Fig. 1c). CH.1.1 pp and XBB.1 pp displayed comparable to slightly higher entry efficiency for Vero, 293 T and Huh-7 cells compared to B.1 pp (1.1x-1.9x higher, compared to B.1 pp), while Caco-2 and Calu-3 cell entry was even less efficient as compared to BA.5 pp (2.3-3.8x reduced, compared to B.1 pp) (Fig. 1c). In accordance with literature, cell entry of XBB.1.5 pp was generally increased compared to XBB.1 pp (1.2-1.5x higher, compared to XBB.1 pp) [4] and the same observation was made for XBB.1.16 pp (1.3-1.6x higher, compared to XBB.1 pp) (Fig. 1c).